The National Pharmaceutical Pricing Authority fixes/revises the price of the Scheduled formulation.
The scheduled formulations are: Atorvastatin + Aspirin Capsule (Atchol-ASP 150), Nifedipine + Lidocaine Cream (LOXHEAL), Pioglitazone + Gliclazide + Metformin Tablet (GLZ Total), Ibuprofen + Paracetamol Tablet (Brufen Plus), Misoprostol Tablet, Glimepiride + Metformin Tablet, Melphalan + Povidone Injection (Melphalan Injection IP 50mg), Trastuzumab Injection, Vitamin D3
(Cholecalciferol) (DRISE SURE), Furosemide Injection, Snake Venom Antiserum-Soluble/ Liquid Polyvalent Injection, and Phenobarbitone oral liquid.
All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price.
The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
